Glaxo Wellcome’s Lotronex account finds home at F-H

WASHINGTON, DC: Glaxo Wellcome has handed a high-six-figure assignment to promote Lotronex, a new irritable bowel syndrome (IBS) treatment, to Fleishman-Hillard.

WASHINGTON, DC: Glaxo Wellcome has handed a high-six-figure assignment to promote Lotronex, a new irritable bowel syndrome (IBS) treatment, to Fleishman-Hillard.

WASHINGTON, DC: Glaxo Wellcome has handed a high-six-figure

assignment to promote Lotronex, a new irritable bowel syndrome (IBS)

treatment, to Fleishman-Hillard.



The thrust of the PR program will be raising consumer awareness of IBS

and the fact that it can be treated. According to Glaxo Wellcome, IBS -

also known as ’nervous stomach’ - may affect as much as 20% of the

population.



Marilyn Castaldi, senior partner and director of Fleishman’s healthcare

practice, said the agency plans to launch a national media relations

campaign to inform consumers about the disease and treatment options.

She said Fleishman’s efforts, to be split between its Washington, DC and

New York outposts, will be targeted at women, who are more commonly

affected by IBS than men.



Castaldi herself will shortly be relocating from New York to DC in order

to better respond to the growing emphasis in the nation’s capital on

healthcare issues. She said her move will allow Fleishman ’to expand,

enlarge and place new emphasis’ on its healthcare practice.



’Healthcare will loom ever larger on the public agenda,’ she said. ’The

DC arena will be a fertile ground for exponential growth.’



Castaldi added that a major factor contributing to healthcare growth is

’demographics. A huge portion of our population is nearing middle age.’



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.